Physician profile
Kara E Boutwell
NPI 1275941601
$12,208.53
in general payments reported to CMS, 2019-2025
68 companies · $2,526 in 2025
The $2,526 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,110 · 2022: $2,547 · 2023: $2,496 · 2024: $2,529 · 2025: $2,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,550.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,488.32 | 2021-2025 | Kisqali, Piqray |
| Merck Sharp & Dohme LLC | $1,007.62 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $894.38 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $627.76 | 2021-2025 | Darzalex, Talvey, Erleada |
| Daiichi Sankyo INC. | $605.40 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $482.89 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Amgen INC. | $482.28 | 2021-2023 | Vectibix, Nplate, Xgeva |
| E.R. Squibb & Sons, L.L.C. | $470.24 | 2021-2025 | Opdivo, Opdualag |
| Eisai INC. | $458.53 | 2021-2025 | |
| Lilly USA, LLC | $447.76 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $430.53 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Pfizer INC. | $378.34 | 2021-2025 | |
| Genentech USA, INC. | $291.14 | 2022-2025 | Tecentriq, Venclexta, Polivy |
| Regeneron Healthcare Solutions, INC. | $277.36 | 2021-2025 | Libtayo, Lynozyfic |
| Genzyme Corporation | $271.48 | 2022-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $263.56 | 2021-2025 | Xospata, Vyloy, Padcev |
| Glaxosmithkline, LLC. | $237.17 | 2021-2025 | Jemperli, Ojjaara, Zejula |
| Exelixis INC. | $232.84 | 2021-2025 | Cabometyx |
| Myriad Genetic Laboratories, INC. | $220.84 | 2022-2023 | Myrisk |
| Ipsen Biopharmaceuticals, INC | $149.23 | 2021-2025 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $146.14 | 2022-2025 | Fruzaqla, Iclusig, Ninlaro |
| Alexion Pharmaceuticals, INC. | $130.12 | 2022-2025 | Ultomiris, Soliris |
| Deciphera Pharmaceuticals INC. | $124.39 | 2021-2025 | Qinlock, Romvimza |
| Beigene USA, INC. | $117.70 | 2022-2025 | Brukinsa, Tevimbra |
| Blueprint Medicines Corporation | $115.12 | 2021-2024 | Ayvakit |
| Array Biopharma INC | $108.94 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmaessentia USA Corporation | $107.36 | 2023-2025 | Besremi |
| Seagen INC. | $105.38 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Abbvie INC. | $89.90 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.24 | 2021-2025 | |
| Puma Biotechnology, INC. | $81.93 | 2022-2024 | |
| Beone Medicines USA, INC. | $77.54 | 2025 | Brukinsa, Tevimbra |
| Coherus Oncology, INC. | $64.77 | 2021-2024 | |
| Tg Therapeutics, INC. | $60.58 | 2021-2022 | |
| Genmab U.S., INC. | $55.32 | 2024-2025 | Epkinly |
| Pharmacosmos Therapeutics INC. | $52.59 | 2025 | Monoferric |
| Emd Serono, INC. | $50.35 | 2023-2025 | Tepmetko |
| Kyowa Kirin, INC. | $50.22 | 2021 | |
| Sumitomo Pharma America, INC. | $50.08 | 2023-2024 | Orgovyx |
| Stemline Therapeutics INC. | $47.09 | 2024-2025 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $44.86 | 2021-2022 | |
| Heron Therapeutics, INC. | $40.99 | 2022 | |
| Sobi, INC | $39.90 | 2022-2024 | |
| Acrotech Biopharma INC. | $37.02 | 2023-2025 | Beleodaq |
| Tersera Therapeutics LLC | $36.32 | 2023 | Zoladex |
| G1 Therapeutics, INC. | $35.12 | 2022-2023 | Cosela |
| Mirati Therapeutics, INC. | $34.69 | 2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $34.66 | 2021-2025 | |
| Caris Mpi, INC. | $33.52 | 2025 | Mi Cancer Seek |
| Morphosys, US INC. | $33.46 | 2022-2023 | Monjuvi |
| Cumberland Pharmaceuticals, INC. | $31.04 | 2024-2025 | Sancuso |
| Karyopharm Therapeutics INC. | $30.92 | 2021-2024 | Xpovio |
| Azurity Pharmaceuticals, INC. | $30.86 | 2024-2025 | Danziten, Vivimusta |
| Servier Pharmaceuticals LLC | $30.31 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $26.87 | 2024 | Clonoseq |
| Gilead Sciences, INC. | $25.62 | 2025 | Trodelvy |
| Tempus Ai, INC | $25.49 | 2024 | |
| Immunogen, INC. | $24.63 | 2023 | Elahere |
| Epizyme, INC. | $23.83 | 2022 | |
| Veracyte, INC. | $20.41 | 2023 | |
| Kite Pharma, INC. | $18.97 | 2025 | Yescarta |
| Spectrum Pharmaceuticals INC. | $17.93 | 2024 | Rolvedon |
| Agios Pharmaceuticals, INC. | $16.71 | 2025 | Pyrukynd |
| Adc Therapeutics America, INC. | $16.70 | 2022 | |
| Rigel Pharmaceuticals, INC. | $14.96 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Progenics Pharmaceuticals, INC. | $14.56 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $14.11 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $13.64 | 2021 |
Drugs and devices associated with these payments
Enhertu $526Keytruda $500Reblozyl $389Kisqali $299Lynparza $273Scemblix $261Lenvima $230Verzenio $210Myrisk $209Jaypirca $207Opdivo $191Libtayo $180Jakafi $166Venclexta $164Cabometyx $153Darzalex $149Imfinzi $148Welireg $146Sarclisa $141Monjuvi $140Brukinsa $132Padcev $128Talvey $125Retevmo $118Jemperli $114Erleada $113Tukysa $111Besremi $107Xospata $101Tecentriq $100Xtandi $99.26Tecvayli $97.70Braftovi $94.57Mektovi $94.57Tasigna $86.96Ibrance $84.85Balversa $83.57Akeega $79.86Pluvicto $78.15Fabhalta $74.79Calquence $74.03Adcetris $71.43Vyloy $70.36Talzenna $70.31Inlyta $70.31Onivyde $69.04Ultomiris $64.82Ojjaara $60.24Piqray $59.91Pomalyst $56.97Epkinly $55.32Lorbrena $52.83Monoferric $52.59Elrexfio $51.51Orgovyx $50.08Xgeva $50.07Nplate $50.07Vectibix $50.07Qinlock $49.15Bosulif $48.72Fruzaqla $47.97Keytruda Qlex $47.52Orserdu $47.09Udenyca $45.80Ayvakit $45.74Promacta $44.55Zynyz $43.13Polivy $41.24Imbruvica $38.23Beleodaq $37.02Zoladex $36.32Mekinist $34.97Tevimbra $34.74Krazati $34.69Rybrevant $34.56Zejula $34.37Mi Cancer Seek $33.52Xalkori $32.88Sancuso $31.04Carvykti $30.52Tibsovo $30.31Datroway $29.84Iclusig $27.08Clonoseq $26.87Injectafer $26.05Trodelvy $25.62Elahere $24.63Soliris $24.10Doptelet $23.84Lynozyfic $23.16Fotivda $20.38Ninlaro $19.27Yescarta $18.97Pemazyre $18.86Cosela $17.95Rolvedon $17.93Xpovio $16.96Tepmetko $16.82Pyrukynd $16.71Tivdak $16.58
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Boutwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.